In phase 2 study of INO-5401 in combination with cemiplimab, Inovio Pharmaceuticals Inc (NASDAQ:INO) achieved success in ensuring the progression-free survival of patients who are diagnosed with GBM (glioblastoma multiforme). The phase 2 study is conducted using INO 9012, and INO 5401 in combination with a PD-1 blocking antibody – Libtayo on fifty-two patients diagnosed […]
Inovio Pharmaceuticals Inc (NASDAQ:INO)
Recent Posts
Colombia Oil and Gas 2023 Congress – Status and Developments Prospects of Oil and Gas industry in Latin America
Mike The Pike Productions, Inc. (OTC: MIKP) Announces Virtual Shareholder Conference July 25, 2023
Künstliche Intelligenz im Kinderherz-Zentrum
Auri Inc. – Dividend, Retirement Timelines and Expectations
Auto Parts 4Less Group, Inc. Unveils Significant Business Progress and Future Plans in Latest Investor Update
Sign Up To Get Our Instant Alerts!
Popular Post
- Tesla Suspends Hiring Further Set to Lay Off 10% of its Labor Force 36 views
- Mike The Pike Productions, Inc. (OTC: MIKP) Announces Virtual Shareholder Conference July 25, 2023 36 views
- Sequoia Capital Raises $2.85 Billion to Fund Indian and Southeast Asian Startups 35 views
- Futuris Company Expands With Historic Building Purchase 34 views
- Auto Parts 4Less Group, Inc. Unveils Significant Business Progress and Future Plans in Latest Investor Update 34 views